NeuroOne is a medical technology company focused on revolutionizing the standard of care for patients suffering from conditions such as epilepsy, Parkinson’s disease, dystonia, essential tremors, and other related brain disorders. We believe our thin film electrodes will be able to be placed with minimally invasive procedures and improve the outcomes for patients with neurological disorders. Additionally, we believe that the higher resolution provided by our electrodes can enable the usage of powerful computing techniques such as machine learning and artificial intelligence.
2017 was a transformational year for us. We completed a reverse merger, up-listed to the OTCQB and raised over $1.8 million in private transactions. Strategically, we established a physician advisory board, completed an early feasibility study for our depth electrode and combination diagnostic/ablation depth electrode1, and filed two provisional patents with the USPTO.
In 2018, we recruited thought leaders and highly renowned AI neurosurgeons to establish our Artificial Intelligence Advisory board. We also established our headquarters, conducted multiple rounds of pre-clinical testing on our ablation electrode2 and a pre-clinical feasibility study for minimally invasive placement of our cortical electrodes at Mayo Clinic3.
For 2019, we expect to debut our cortical electrodes, pending FDA 510(k) clearance. We submitted a 510(k) filing to the FDA for our cortical electrode product line and plan to submit our depth electrode product line later this year. Upon clearance, we intend to launch our electrode products to targeted industry leading, medical centers. We also plan on exploring additional product applications with insight from our AI advisory board.
NeuroOne entered into a license and development agreement with Mayo Clinic. NeuroOne licensed worldwide certain know how for the development and commercialization of products, methods and processes related to flexible circuit thin film technology for the recording of tissue and the products developed therefrom.
Wisconsin Alumni Research Foundation
NeuroOne entered into an Exclusive Start-Up Company License Agreement with the Wisconsin Alumni Research Foundation (WARF). WARF granted NeuroOne an exclusive license to make, use and sell, in the U.S. products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method.
NeuroOne is developing minimally invasive solutions for brain related disorders which include epilepsy, essential tremors, Parkinson’s disease, dystonia and other neurological conditions. We are focused on the development and commercialization of thin film electrodes for use in Intracranial (iEEG) recording and stimulation for Electrocorticography (ECoG), Stereoelectroencephalography (sEEG), ablation as well as electrodes capable of providing chronic stimulation.
Our electrodes have a new thin film technology which may reduce patient complications during procedures, allow for minimally invasive placement, are designed to provide better signal clarity in recording brain activity for diagnosis, and may reduce the cost of care while improving patient outcomes.
Why NeuroOne’s Electrode Solution is Better
In comparison to currently available technologies, we are developing thin film electrodes with the goal of reducing overall procedure times, reducing the invasiveness and risks of the procedure, improving the comfort of the patient, and improving the accuracy of diagnosis so patients suffering from neurological disorders may have a better quality of life.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for NeuroOne Medical Technologies Corporation current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF NeuroOne Medical Technologies Corporation
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.